课题基金 / 基金详情

The role of the RNA helicase DDX3X in Burkitt Lymphoma and its potential as a new therapeutic target

The role of the RNA helicase DDX3X in Burkitt Lymphoma and its potential as a new therapeutic target
RNA解旋酶DDX3X在伯基特淋巴瘤中的作用及其作为新治疗靶点的潜力
批准号：
461753
负责人：
Moroy Tarik
金额：
$84.71万
依托单位：
Institut de recherches cliniques de Montral
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
未结题
起止时间：
2022-03-01 至 2027-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=461753&lang=en
关键词：
B-Cell Lymphoma Rna Helicases

项目摘要

项目成果

Moroy Tarik的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Burkitt lymphoma is a blood cancer, which manifests itself as masses of tissue in the neck or jaw, often disfiguring the patients. This disease occurs very frequently in children and is treated by surgical removal of the tumor masses, followed by chemothe
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The MYC/MIZ-1 complex in germinal center B cells and B cell lymphomagenesis
Therapeutic potential of the long non-coding RNA ELDR for the Acute Myeloid Leukemia subtype M5 with t(9;11) translocations
Transcriptional control of hematopoiesis, immune cell differentiation and leukemia
Canada Research Chair Tier 1
  • 批准号：
    315435
  • 项目类别：
  • 资助金额：
    $101.99万
  • 财政年份：
    2014
  • 负责人：
    Moroy Tarik
  • 依托单位：
    Universit de Montral
海外基金